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The antibacterial activity of the compounds egonol (1) and homoegonol (2), of the crude ethanolic 
extract of Styrax pohlii (Styracaceae) aerial parts (EE), and of its n-hexane (HF), EtOAc (EF), n-BuOH 
(BF), and hydromethanolic (HMF) fractions was evaluated against the following microorganisms: 
Streptococcus pneumoniae (ATCC 6305), S. pyogenes (ATCC 19615), Haemophilus influenzae (ATCC 
10211), Pseudomonas aeruginosa (ATCC 27853), and Klebsiella pneumoniae (ATCC 10031). The 
broth microdilution method was used for determination of the minimum inhibitory concentration (MIC) 
during preliminary evaluation of antibacterial activity. The EE yielded MIC values of 400 µg/mL for 
S. pneumoniae and P. aeruginosa and 300 µg/mL for H. influenzae. The HF and EF fractions exhibited 
enhanced antibacterial activity, with MIC values of 200 µg/mL against S. pneumoniae, but only EF 
displayed activity against H. influenzae (MIC 200 µg/mL). The best MIC value with compounds 1 and 
2 (400 µg/mL) was obtained for (1) against S. pneumoniae and P. aeruginosa. Therefore, 1 exhibited 
weak antibacterial activity against these standard strains.
Uniterms: Styrax pohlii/pharmacognosy. Styracaceae/pharmacognosy. Styrax pohlii/ethanolic extract/
antibacterial activity. Egonol/antibacterial activity. Homoegonol/antibacterial activity. Natural products/
evaluation.
As atividades antimicrobianas das substâncias egonol (1) e homoegonol (2), do extrato etanólico 
das partes aéreas de Styrax pohlii (Styracaceae) (EE), bem como das frações n-hexano (HF), AcOEt 
(EF), n-BuOH (BF) e hidrometanólica (HMF) foram avaliadas frente aos seguintes microorganismos: 
Streptococcus pneumoniae (ATCC 6305), S. pyogenes (ATCC 19615), Haemophilus influenzae (ATCC 
10211), Pseudomonas aeruginosa (ATCC 27853) e Klebsiella pneumoniae (ATCC 10031). O método 
de microdiluição em caldo foi utilizado para a determinação da concentração inibitória mínima (CIM) 
na avaliação preliminar da atividade antimicrobiana. EE mostrou valores de CIM de 400 µg/mL para S. 
pneumoniae e P. aeruginosa, e 300 µg/mL para H. influenzae. As frações HF e EF apresentaram melhora 
na atividade antimicrobiana, com valores de CIM de 200 µg/mL frente S. pneumoniae, mas apenas EF 
apresentou ação contra H. influenzae (200 µg/mL). Em relação às substâncias 1 e 2, o melhor valor de 
CIM (400 µg/mL) foi obtido por 1 frente a S. pneumoniae e P. aeruginosa, que exibiu fraca atividade 
antimicrobiana contra estas cepas padrões.
Unitermos: Styrax pohlii/farmacognosia Styracaceae/farmacognosia. Styrax pohlii/extrato etanólico/
atividade antimicrobiana. Egonol/atividade antimicrobiana. Homoegonol/atividade antimicrobiana. 
Produtos naturais/avaliação.
INTRODUCTION
A major concern in the public health field is the ease 
of development of antibiotic resistance by bacteria, since 
infectious diseases caused by resistant microorganisms 
are responsible for increased health costs as well as 
high morbidity and mortality, particularly in developing 
countries (Nickerson et al., 2009a; 2009b; Gangoué-Piéboji 
et al., 2009). The rapid emergence of bacterial resistance is 
attributable to such diverse factors as the complex genetics 
of the microorganism; the increasing transport of humans, 
animals, and goods between countries; the widespread use 
of antibiotics; and the lack of precise therapeutic choices 
for high-risk patients (Stefani, 2009).
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Natural medicinal products have been used for 
millennia to treat various ailments. Although many 
have been superseded by conventional pharmaceutical 
approaches, there is a resurgence of interest in natural 
products by physicians (Boukraa, 2008; Shimizu et al., 
2001). In addition, the existence of resistant bacterial 
strains reinforces the need for development of novel safe 
and effective antibacterials that can combat infectious 
diseases caused by bacteria (Gangoué-Piéboji et al., 2009; 
Coutinho et al., 2009).
The literature describing traditional Brazilian 
medicine contains references to the use of plant species 
belonging to the genus Styrax (Styracaceae), which have 
been mainly employed in the treatment of gastrointestinal 
diseases and fevers. Styrax pohlii A. DC., known in Brazil 
as “pindaíba”, “pindaúba”, “benjoeiro”, “estoraqueiro”, 
and “árvore-de-bálsamo”, is used as a folk medicine to 
relieve fever (Lorenzi, 1998; Rodrigues, Carvalho, 2008). 
It grows in the States of São Paulo, Minas Gerais, Goiás, 
and Mato Grosso do Sul, mainly in the Cerrado region, a 
biome characterized by rich biodiversity but threatened 
by agriculture (Lorenzi, 1998; Ratter et al., 1997). 
Phytochemical investigations of Styrax species have 
revealed a predominance of shikimate derivatives, such 
as lignan derivatives of 3,7-dioxabicyclo[3.3.0]octane, 
butanolide, and tetrahydrofuran; neolignan derivatives 
of dihydrobenzofuran; nor-neolignan derivatives of 
benzofuran, phenylpropanoids, and phenolic acids; and 
pentacyclic saponins and triterpenes (Pauletti et al., 2006). 
Previous studies have shown that some lignans, neolignans 
and nor-neolignans from Styrax and their derivatives 
display significant antimicrobial and cytotoxic activities 
(Pauletti et al., 2000; Teles et al., 2005; Hirano et al., 1994; 
Öztürk et al., 2008).
Therefore, as part of our ongoing biological studies 
into the antibacterial activity of natural compounds 
(Pauletti et al., 2000; Scalon Cunha et al., 2007; Cunha et 
al., 2010; Silva et al., 2009), we now provide a preliminary 
report on the antibacterial activities of compounds 1-2, 
the crude ethanolic extract (EE), and the n-hexane (HF), 
EtOAc (EF), n-BuOH (BF), and hydromethanolic (HMF) 
fractions of Styrax pohlii against the microorganisms 
Streptococcus pneumoniae, S. pyogenes, Haemophilus 
influenzae, Pseudomonas aeruginosa, and Klebsiella 
pneumoniae, which have not yet been described.
MATERIAL AND METHODS
Collection and identification
S. pohlii A. DC. was collected in the municipality of 
Luis Antonio, state of São Paulo, Brazil, in October 2008, 
and identified by Prof. V. M. M. Gimenez and Prof. M. 
Groppo. A voucher specimen (SPFR12168) was deposited 
in the Herbarium of the Faculdade de Filosofia, Ciências 
e Letras de Ribeirão Preto, Universidade de São Paulo.
Extraction and isolation
The air-dried, powdered stems and leaves (2.43 kg) 
of S. pohlii were extracted with EtOH by maceration 
at room temperature. After filtration, the solvents 
were removed under reduced pressure to yield 87.2 g 
of extract. The EE (20.3 g) was then dissolved in 
MeOH/H2O (1:4, v/v) and successively partitioned with 
n-hexane, EtOAc, and n-BuOH. After solvent removal 
using a rotary evaporator, each partition phase yielded 
1.39, 2.97, and 3.80 g of extract respectively. Additionally, 
the residual hydromethanolic phase furnished 4.12 g. In 
a previous study, our research group had fractionated the 
n-hexane fraction and obtained compounds 1 (27.3 mg) 
and 2 (22.0 mg) (Bertanha et al, 2012).
Antibacterial assay
The following microorganisms were used for 
evaluation of antibacterial activity: Streptococcus 
pneumoniae (ATCC 6305), S. pyogenes (ATCC 19615), 
Haemophilus influenzae (ATCC 10211), Pseudomonas 
aeruginosa (ATCC 27853), and Klebsiella pneumoniae 
(ATCC 10031). Minimum inhibitory concentration (MIC) 
values for each sample were determined in triplicate by 
using the broth microdilution method (CLSI, 2009). The 
samples were dissolved in DMSO (Merck) at 0.5 mg/mL 
 and then diluted in Brain Heart Infusion broth or, for 
H. influenzae only, BD Haemophilus Test Medium Agar 
(Difco Labs), to concentrations ranging from 400 to 
20 μg/mL. The final DMSO concentration in the culture 
medium was 5% (v/v), which was used as a negative 
control. The inoculum was adjusted to each organism to 
yield a cell concentration of 5×105 colony forming units 
(CFU/mL). One inoculated well was included to control 
the adequacy of the broth for organism growth. One 
non-inoculated well, free of antibacterial agent, was also 
included to ensure medium sterility. Chloramphenicol and 
vancomycin were used as controls, dissolved in DMSO 
(Merck) at 0.1 and 10 mg/mL respectively, and then 
diluted in Brain Heart Infusion broth or BD Haemophilus 
Test Medium Agar to 0.02 mg/mL. The controls were 
evaluated at final concentrations ranging from 0.01 to 
5.9 μg/mL. The microplates (96-well) were incubated at 
37 °C for 24 h. Then, 30 μL of resazurin 0.01% aqueous 
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TABLE I - Minimum inhibitory concentration values (MIC) obtained for the crude ethanolic extract of S. pohlii, fractions and 
isolated compounds
Sample
MIC [μg/mL]
K. pneumoniae P. aeruginosa S. pyogenes S. pneumoniae H. influenzae
EE > 400 400 > 400 400 300
HF > 400 400 > 400 200 > 400
EF > 400 400 400 200 200
BF > 400 400 > 400 400 400
HMF > 400 400 > 400 > 400 > 400
Egonol (1) > 400 400 > 400 400 > 400
Homoegonol (2) > 400 > 400 > 400 > 400 > 400
Positive Controlsa 0.046 (c) 5.9 (c) 0.37 (v) 0.37 (v) 0.046 (c)
aPositive Controls: (c)- Chloranphenicol (v)- Vancomycin
solution (Sigma-Aldrich) was added to determine 
microorganism viability (Sarker et al., 2007). The MIC 
was determined as the lowest concentration of the sample 
capable of inhibiting microorganism growth.
RESULTS AND DISCUSSION
A previous study on the CH2Cl2-CH3OH (2:1, v/v) 
crude extract from the leaves of S. ferrugineus demonstrated 
antimicrobial activity, as detected by inhibition of 
Cladosporium sphaerospermum, Candida albicans, and 
Staphylococcus aureus (Pauletti et al., 2000). This finding 
has encouraged us to conduct biological and chemical 
investigations of metabolites isolated from other species 
of this genus.
Regarding the antibacterial assay, the crude EtOH 
extract (EE), as well as the n-hexane (HF), EtOAc (EF), 
n-BuOH (BF), and hydromethanolic (HMF) fractions of 
S. pohlii, were screened for their antibacterial activity 
against five different bacterial strains, three of which 
were Gram-positive and two were Gram-negative. The 
preliminary antibacterial activities, expressed as the MIC, 
are shown in Table I.
The EtOH extract (EE) yielded MIC values of 
300 μg/mL against H. influenzae and 400 μg/mL against 
S. pneumoniae and P. aeruginosa. EE did not inhibit 
the growth of the two other tested strains. Therefore, 
EE exhibits moderate activity against H. influenzae, S. 
pneumoniae and P. aeruginosa, as described by Holetz 
et al. (2002).
Compared with EE, the n-hexane fraction (HF) 
provided superior antibacterial activity against the Gram-
positive S. pneumoniae, with a MIC value of 200 μg/mL. 
However, unlike EE, HF did not significantly reduce the 
growth of H. influenzae. In addition, HF displayed an MIC 
of 400 μg/mL against P. aeruginosa, but was considered 
ineffective against S. pyogenes, H. influenzae, and K. 
pneumoniae. According to these results, the HF fraction 
exhibits promising activity against S. pneumoniae.
The best MIC value obtained for the EtOAc fraction 
(EF) was 200 μg/mL, against the Gram-negative H. 
influenzae and the Gram-positive S. pneumoniae. This 
result is superior to those obtained with EE against the 
same strains (MIC = 300 and 400 μg/mL, respectively). 
In addition, EF displayed an MIC of 400 μg/mL against 
P. aeruginosa and S. pyogenes. Thus, EF was the only 
assayed sample that exhibited moderate antibacterial 
activity against S. pyogenes, as compared with the data 
obtained by Holetz et al. (2002).
The n-BuOH fraction (BF) exhibited moderate 
antibacterial  activity against  P. aeruginosa ,  S. 
pneumoniae, and H. influenzae (MIC = 400 μg/mL), and 
did not significantly inhibit the growth of the two other 
tested strains, just as found for EE. The hydromethanolic 
fraction (HMF) displayed moderate antibacterial activity 
against P. aeruginosa. Thus, the BF and HMF fractions 
are not promising antibacterials against the strains 
tested in this work when compared with the HF and EF 
fractions.
In conclusion, differences in antibacterial effect were 
more evident for the HF fraction when assayed against the 
tested Gram-positive bacteria. HF was not effective against 
Gram-negative bacteria, perhaps due to the presence of the 
outer membrane in the latter microorganisms (Horiuchi et 
al., 2007). The HF fraction was thus selected for a further 
purification process as described previously (Bertanha et 
al., 2012), which yielded egonol (1) and homoegonol (2) 
(Figure 1).
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Regarding the antibacterial activity of the isolated 
compounds (Table I), egonol (1) displayed weak 
activity against P. aeruginosa and S. pneumoniae 
(MIC = 400 μg/mL), according to Ríos and Recio 
(2005). As HF displayed the same activity as 1 against 
P. aeruginosa, it might be suggested that 1 is the compound 
responsible for the activity initially observed for the HF 
fraction, at least against P. aeruginosa. However, data for 
S. pneumoniae showed that 1 displayed half of the activity 
found for HF against this same strain. Similar findings are 
frequently observed in the area of natural product research 
after fractionation processes (Harvey, 2009; Yeh et al., 
2012). Homoegonol (2) was considered inactive, at least 
in the present assay conditions.
Compounds 1 and 2 are quite similar, differing 
mainly in the presence of a methylenedioxyl group 
or two methoxyl groups at the phenyl ring connected 
to C-2 of the 5-propylbenzofuran core, respectively. 
Therefore, considering their antibacterial activity, it can 
be suggested that the presence of a methylenedioxyl group 
in compound 1 may improve its activity, since it was 
more active than compound 2. The mechanism whereby 
benzofuran derivatives exert their in vitro antibacterial 
effect is unclear. However, 1, 2, and some semi-synthetic 
egonol derivatives have been shown to possess antifungal 
and antibacterial activities against several species, 
including Staphylococcus aureus, Candida albicans, 
Cladosporium sphaerospermum, Bacillus subtilis, and 
Escherichia coli (Pauletti et al., 2000; Öztürk et al., 2008). 
Nevertheless, further studies are still required to improve 
the antibacterial activity of these natural products and 
obtain a better understanding of the mode of action of 
benzofuran derivatives.
CONCLUSION
The EtOH extract (EE) of S. pohlii showed moderate 
activity against the Gram-negative bacterial species H. 
influenzae. Chemical analysis of the EE yielded four 
fractions. The n-hexane fraction exhibits promising activity 
FIGURE 1 - Chemical structures of the compounds isolated.
against the Gram-positive S. pneumoniae bacterium and 
was thus selected for further purification, which yielded 
egonol (1) and homoegonol (2). Furthermore, biological 
assay results suggested that compound 1 inhibits the 
growth of P. aeruginosa and S. pneumoniae. Further 
studies are ongoing to assess other potentially important 
biological effects of this plant species.
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